Guillain-Barré syndrome Prof Hugh J Willison, MBBS, Prof Bart C Jacobs, MD, Prof Pieter A van Doorn, MD The Lancet Volume 388, Issue 10045, Pages 717-727 (August 2016) DOI: 10.1016/S0140-6736(16)00339-1 Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 1 Guillain-Barré syndrome time course The Lancet 2016 388, 717-727DOI: (10.1016/S0140-6736(16)00339-1) Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 2 Major Guillain-Barré syndrome subtypes in which antibody-mediated effector pathways, including complement activation, cause glial or axonal membrane injury with consequent conduction failure The Lancet 2016 388, 717-727DOI: (10.1016/S0140-6736(16)00339-1) Copyright © 2016 Elsevier Ltd Terms and Conditions
Figure 3 Treatment approach for Guillain-Barré syndrome Modified with permission from van den Berg and colleagues.4 Solid lines are treatment flow; dashed lines are issues that need to be considered. ICU=intensive care unit. EGRIS=Erasmus GBS Respiratory Insufficiency Score. IVIg=intravenous immunoglobulin. TRF=treatment related fluctuation. The Lancet 2016 388, 717-727DOI: (10.1016/S0140-6736(16)00339-1) Copyright © 2016 Elsevier Ltd Terms and Conditions